Glenmark Pharmaceuticals Ltd update on USFDA PAI at Chhatrapati Sambhajinagar Facility

The U.S. Food and Drug Administration (U.S. FDA) completed Pre-Approval Inspection at Glenmark Pharmaceuticals Limited's formulations manufacturing facility in Chhatrapati Sambhajinagar (Aurangabad).

The inspection was carried out from November 24 to November 28, 2025, and concluded with zero 483 observations.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1947.25 as compared to the previous close of Rs. 1942.95. The total number of shares traded during the day was 12369 in over 1206 trades.

The stock hit an intraday high of Rs. 1968.45 and intraday low of 1938.10. The net turnover during the day was Rs. 24135248.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USFDA PreApprovalInspection FormulationsManufacturingFacility ChhatrapatiSambhajinagar